Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: FOSAMAX

« Back to Dashboard
Fosamax is a drug marketed by Merck and Merck And Co Inc and is included in three NDAs. It is available from two suppliers. There are four patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in FOSAMAX is alendronate sodium; cholecalciferol. There are twenty-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alendronate sodium; cholecalciferol profile page.

Summary for Tradename: FOSAMAX

Suppliers / Packagers: see list6

Pharmacology for Tradename: FOSAMAX

Drug ClassBisphosphonate

Clinical Trials for: FOSAMAX

FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
Status: Completed Condition: Osteoporosis

The Effects of Alendronate After Cure of Primary Hyperparathyroidism
Status: Withdrawn Condition: Hyperparathyroidism

Pilot Study of Fosamax in Spinal Cord Injury
Status: Terminated Condition: Spinal Cord Injury; Osteoporosis

Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions
Status: Completed Condition: Healthy

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury Previously Treated With Teriparatide
Status: Enrolling by invitation Condition: Spinal Cord Injury; Bone Loss; Osteoporosis

Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss
Status: Not yet recruiting Condition: Bone Demineralization

Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
Status: Completed Condition: Osteoporosis Postmenopausal

Alendronate in Juvenile Osteoporosis
Status: Completed Condition: Juvenile Osteoporosis; Low Bone Density; Fractures

Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
Status: Completed Condition: Cystic Fibrosis; Osteoporosis; Bone Diseases, Metabolic

Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis
Status: Completed Condition: Osteoporosis

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
alendronate sodium
SOLUTION;ORAL021575-001Sep 17, 2003RXYes6,225,294*PED<disabled>Y<disabled>
Merck And Co Inc
alendronate sodium
TABLET;ORAL020560-004Oct 20, 2000DISCNNo<disabled><disabled>
alendronate sodium
SOLUTION;ORAL021575-001Sep 17, 2003RXYes5,462,932*PED<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FOSAMAX

Drugname Dosage Strength RLD Submissiondate
alendronate sodium and cholecalciferolTablets70 mg/2800 IU and 70 mg/5600 IUFosamax Plus D11/20/2007
alendronate sodiumOral Solution70 mg/75 mLFosamax9/7/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn